Taking lead screening to the next level
BioCopy provides the shortcut to finding the right candidate for future tumor and autoimmune therapeutics. Our cutting-edge microarray technology provides efficient immune profiling and lead screening of T-cell receptors (TCR), bi- and multispecifics, and other biomolecules against thousands of antigen-HLA complexes in parallel.
We're your partner
When R&D gets slow and complex in your T-cell drug discovery program and you need complete binding kinetic data of thousands of molecular interactions in short time, BioCopy is your partner. We are globally leading for speed and throughput in molecular interaction analysis.
At BioCopy, we make lead finding and characterization in your R&D program for T-cell therapy drug discovery highly efficient. With our technology and expertise, we simultaneously analyze interactions of TCR, bi- and multispecifics, and other biomolecules for binding against thousands of peptide-HLA complexes. Our proprietary microarray system investigates up to 5,000 interactions with peptide-HLA in parallel, within a single measurement, and including the analysis of binding kinetics. This enables the identification of lead candidates from highly complex libraries, comprising thousands of tumor and other disease-specific antigens for future treatments in oncology and autoimmune diseases.
BioCopy provides you with complete data sets within days, saving months of R&D time as well as large amounts of R&D specimen compared to other techniques, such as Biolayer Interferometry (BLI) or Surface Plasmon Resonance (SPR).
Partnerships & Collaborations
In 2021, Immatics Biotechnologies
In 2021, Immatics Biotechnologies implemented BioCopy’s technology in Immatics’ in-house XCEPTOR® platform. This allows Immatics to benefit from the speed and capabilities of BioCopy’s technology in their drug development programs. BioCopy has established further collaborations with undisclosed partners; additional partnering activities are in progress.
With the novel, patented T-cell therapy screening technology, BioCopy will accelerate and improve T-cell therapy development. It is one of the few companies worldwide who can support targeted therapy development for both pathways (B-cell and T-cells) of the immune system.
Former Chief Commercial and Medical Affairs Officer at Novartis Pharma and Member of the Board of Directors at BioCopy